2 which belong to two types, the a platelet receptors and the T vascular receptors. 3 Because of its biological properties, TxA 2 may be involved in blood pressure regulation and participate in the pathophysiology of genetic hypertension. This latter hypothesis is supported by the fact that increased TxA 2 biosynthesis or concentrations are observed in isolated perfused kidneys 4 and in glomeruli, 5 as well as in urine 6 -7 and serum 6 ' 8 of spontaneously hypertensive rats (SHR) of the Japanese strain. In another model of genetic hypertension, the Lyon model, 9 we described a higher TxA 2 renal production in young (5-and 9-week-old) but not in adult Lyon genetically hypertensive (LH) rats compared with their two control normotensive strains. 10 Such an alteration in TxA 2 biosynthesis seems to be specific to genetic hypertension, as it is not found in models that 12 rats. The antihypertensive effect of chronic Tx synthetase inhibition in SHR led to controversial observations. Grone et al 6 observed no change in systolic blood pressure (SBP) after long-term treatment with Dazmegrel, a Tx synthetase inhibitor, or with Dazmegrel combined with EP 092, a TxAz/PGHj receptor antagonist. BM 13505, another TxA/PGH 2 receptor antagonist, failed to reduce SBP in SHR rats. 13 By contrast, others 7 ' 814 obtained a reduction in the blood pressure elevation or a delay in the development of hypertension by using different thromboxane synthetase inhibitors such as OKY 046, 7 4'(hnidazol-1-yl) acetophenone, 8 or CV 4151. 14 The present study was undertaken to determine whether the increased renal synthesis of TxA 2 , which we described in young LH rats, 10 could participate in the development of hypertension. This was-assessed by studying the effects of long-term treatment with two different thromboxane synthetase inhibitors or with a TxAj/PGH 2 receptor antagonist given during the prehypertensive stage.
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Hypertension Vol 16, No 6, December 1990 excludes the contamination of urines with prostaglandin-containing seminal fluid. The rats were housed under strictly controlled conditions of temperature (21±1°C), lighting (12- hour light/dark cycle, 8 AM-8  PM) , and humidity (60±10%). They received a regular diet (UAR AO3 Entretien, UAR, Villemoisson/Orge, France) and had free access to tap water.
Drugs
Two specific Tx synthetase inhibitors, Dazmegrel and OKY 046, and one TxAj/PG^ receptor antagonist, AH 23848, were used. Dazmegrel (UK 38485: 3-(l//-imidazol-l-yl-methyl)-2-methyl-l//-indol-l-propanoic acid), supplied by Pfizer Central Research, Sandwich, Kent, England, was suspended in arabic gum (10% weight/volume) and administered by gavage. In preliminary experiments, we used the dose of 100 mg/kg/day usually found in the literature. 615 ' 16 It was reduced to 75 mg/kg/day in the rats aged from 3 to 5 weeks because we observed toxic effects. OKY 046 ((£)-3-[/?-(l//-imidazol-l-yl-methyl)phenyl]-2-propanoic acid) was obtained from Ono Pharmaceutical Company Limited, Osaka, Japan. According to Purkerson et al, 7 it was dissolved in NaCl 0.9% and given at the dose of 20 mg/kg body wt twice dairy by the subcutaneous route. AH 23848
, supplied by Glaxo Group Research Limited, Greenford, Kent, England, was dissolved in sodium bicarbonate 8% (weight/ volume). Preliminary experiments, using platelet aggregation as an index of TxAJ?Gi\ 2 receptor blockade, were designed to determine the dose to be used. They showed an inhibition of 65.7±4.5% (n=4), 83.9±0.6% (n=5), and 91.8±1.0% (n=3) 1 hour after a single oral dose of 1, 2, and 4 mg/kg, respectively. The dose of 2 mg/kg inhibited platelet aggregation by 86.3 ±3.7% (n=l) and 72.1±0.3% (n=7) at 12 and 24 hours, respectively, after a single oral administration. Therefore, the dose of 2 mg/kg twice daily was chosen. The slow onset of the antihypertensive action of AH 23848 observed in the present study and reported below led us to determine the kinetics of the vascular TXA2/PGH2 receptor blockade by AH 23848. For that purpose, 8-week-old female rats (five LN and five LH rats) were prepared with arterial and venous femoral catheters, which were tunneled subcutaneously and exteriorized between scapulae. One day later, the arterial catheter was connected to a blood pressure transducer (model P23ED, Statham, Cleveland, Ohio) coupled to a blood pressure analyzer (Gould processor amplifier, model 134615-52, Cleveland, Ohio). The venous catheter was used for bolus injections of a submaximal dose (5 Mg/kg) of U46619 (Sigma Chemical Co., St. Louis), a TXA2/PGH2 receptor agonist, 3 which were performed before and after an oral administration of 2 mg/kg AH 23848. In the two strains, basal SBP levels remained unchanged after AH 23848 administration. As shown in Figure 1 , the pressor effect of U46619 recovered by 50% 3 hours after AH 23848 administration and returned to control levels 5 hours after. 
Protocols
Thromboxane synthetase inhibition with Dazmegrel. Experiment 1 was conducted in groups of 12 female LH rats gavaged, from the fifth to the ninth week of age, with 100 mg/kg/day Dazmegrel or with vehicle. The SBP was recorded weekly from 5 to 11 weeks of age. The urinary excretion of PGs and electrolytes was measured at 6 weeks of age (6 days after the beginning of treatment) and at 9 weeks of age (during the last 24 hours of treatment).
In experiment 2, the treatment was initiated from the time of weaning (i.e., in 3-week-old animals). Two groups of 12 female LH rats were orally given either vehicle or Dazmegrel at the dose of 75 mg/kg/ day from 3 to 5 weeks and 100 mg/kg/day from 5 to 9 weeks of age. SBP was measured weekly from 5 to 11 weeks of age, whereas the urinary excretion of PGs and electrolytes was determined in 5-and 9-week-old rats (i.e., after 2 and 6 weeks of treatment). Creatinine clearance was measured in 9-week-old animals.
Thromboxane synthetase inhibition with OKY 046. One group of 12 female LH rats subcutaneously received OKY 046 (20 mg/kg body wt b.i.d.). Twelve LH and 12 LN female rats received the same volume of NaCl 0.9% and served as controls. SBP of the three groups of rats was followed from 5 to 11 weeks of age and, in LH rats only, the urinary excretion of PGs and electrolytes and creatinine clearance were studied as in Dazmegrel experiment 2.
Thromboxane A 2 receptor blockade. From 3 to 9 weeks of age, LH female rats (n=12) were gavaged with 2 mg/kg AH 23848 twice daily, and 12 LH and 12 LN female rats received the vehicle and served as controls. The SBP was followed from 5 to 12 weeks of age. As in the two aforementioned experiments, the urinary excretion of electrolytes was determined in 5-and 9-week-old animals. At 9 weeks of age, urines were collected for PG measurement in LH rats only. Twelve hours after the last dose, while the rats were under light ether anesthesia, blood was obtained from the jugular vein in one half of LH rats for platelet aggregation study and in the other half for the measurement of plasma creatinine.
Methods
SBP was recorded weekly immediately before the administration of drugs or vehicle by an indirect tail plethysmographic method (Narco Biosystems, Houston) in the prewarmed (37° C for about 10 minutes) unrestrained conscious rat. At least three readings were obtained by a blinded investigator and averaged for each animal and each time. The 24-hour urinary excretion of TxBj, 6-keto-PGF la , and PGEz was used as an index of the renal production of TxA 2 , prostacyclin (PGI 2 ), and PGEj, respectively.
1718 It was determined using our previously described method. 19 In this technique, urinary PGs and TxB2 were first extracted by ethyl acetate and then submitted, before specific radioimmunoassays, to a reversed phase, high-performance liquid chromatographic separation performed on a column packed with Nucleosil C18 (particle size, 10 ^m) using a mobile phase made of water, acetonitrile, and acetic acid (79^21 : 0.1) at a flow rate of 2.3 ml/min. This step is of major importance as it allows a separation of 6-keto-PGF la , TxBâ nd PGE2 from the other primary PGs and also of 6-keto-PGF la and TxBj from their respective dinor derivatives, which are influenced by the systemic production of PGI 2 and TxA 2 . Therefore, although our anti-6-keto-PGF la and anti-TxB 2 antibodies partly cross-reacted with the corresponding dinor derivatives (10.7% and 26.7%, respectively), any interference was avoided during the radioimmunoassays. The urinary excretion of Na + and K + was determined by flame photometry (IL meter). Urinary and plasma creatinine were measured according to Jaffe's colorimetric method. TxA 2 receptor blockade was assessed by the inhibition of platelet aggregation. 20 Starting with a citrated blood sample (5 ml), platelet aggregation study was performed using a dilution of platelet-rich plasma (PRP) (centrifugation 130g, 10 minutes) with platelet-poor plasma (PPP) (centrifugation l,000g, 15 minutes) provided by the same rat. The test was realized in triplicate in disposable polystyrene cuvettes containing 0.5 ml PRP stirred at 1,100 rpm during 1 minute in the aggregometer. Platelet aggregation was induced by bovine thrombin (Hoffman Laroche, Basel, Switzerland) used at the concentration of 3 units/ml diluted in Tyrode's solution (pH 7.4).
Statistical Analysis
Results are expressed as mean±SEM. The data were analyzed by Student's t test for unpaired data (experiments 1, 2, 3, and 4) and by an analysis of variance for repeated measurements (study of the kinetics of the vascular TxA2/PGH 2 receptor blockade). • 
Results

Thromboxane Synthetase Inhibition
When started at 5 weeks of age, long-term treatment with Dazmegrel did not influence SBP of LH rats (Figure 2 ) despite an inhibition of TxBj urinary excretion of 34% (15.6±2.4 versus 9.7±1.1 ng/24 hr) and 54% (6.3±1.1 versus 2.9±1.1 ng/24 hr) after 1 and 4 weeks of treatment, respectively (Figure 3) . Dazmegrel did not modify either 6-keto-PGF, a and PGE2 urinary excretion or diuresis, natriuresis, and kaliuresis (Table 1) .
When started at 3 weeks of age, Dazmegrel and OKY 046, at the doses used, induced a similar inhibition of the TxB 2 urinary excretion ( Figure 3 ) without modifying that of 6-keto-PGF la and PGF (  Table 2 ). In both cases, the Tx synthetase inhibition was progressive, as the degree of inhibition was 35% 
Age (weeks) FIGURE 3. Bar graphs showing urinary excretion of thromboxane (Tx) B 2 in groups of 12 Lyon hypertensive (LH) rats during chronic Tx synthetase inhibition with Dazmegrel between 5 and 9 weeks of age (panel A) and with Dazmegrel or OKY 046 between 3 and 9 weeks of age (panel B). Arrows indicate start and end of treatments.
(17.2±1.5 versus 11.2+0.9 ng/24 hr) and 29% (18.0±1.3 versus 12.7±1.2 ng/24 hr) after 2 weeks and 62% (2.6±0.4 versus 1.0±0.3 ng/24 hr) and 57% (6.8±0.5 versus 2.9±0.2 ng/24 hr) after 6 weeks of treatment for Dazmegrel and OKY 046, respectively. Diuresis, natriuresis, kaliuresis, and creatinine clearance were not influenced by either Dazmegrel or OKY 046 ( Table 2 ). As shown in Figure 2 , Dazmegrel treatment attenuated transiently (at the ages of 6 and 7 weeks only) the rise of SBP, whereas OKY 046 resulted in a normalization of SBP in 6-, 7-, and 8-week-old LH rats. Despite continuing the treatment, the antihypertensive effect of OKY 046 declined at 9 weeks of age and disappeared immediately after its cessation.
Thromboxane A 2 receptor blockade. Six weeks of long-term treatment with AH 23848 induced a platelet aggregation inhibition of 64.7±3.9%. AH 23848 did not modify the urinary excretion of TxB? (6.0±0.7 versus 6.6±0.9 ng/24 hr), 6-keto-PGF la and PGE^ or the renal function parameters ( Table 2 ). As shown in Figure 4 , AH 23848 exerted a delayed but pronounced antihypertensive effect that appeared after 3 weeks of treatment and resulted in a normalization of SBP in 6-, 7-, and 8-week-old LH rats, which lasted 1 week after the end of the treatment.
Discussion
The present work demonstrates that TxA 2 or PGH 2 are likely to participate in the development of hypertension in LH rats. However, it raises several questions because 1) two structurally related Tx synthetase inhibitors that induced a similar and progressive decrease in urinary TxB2 exhibited different antihypertensive properties and 2) only a TXA2/PGH2 receptor antagonist was able to normalize, in a stable manner, the blood pressure of LH rats. Finally, it must be emphasized that the antihypertensive properties of Tx synthetase inhibitors or of TXA2/PGH2 receptor blockers required several weeks to become significant. Taken as a whole, these results suggest that the role of TxA 2 or of PGH 2 in genetic hypertension may be indirectly related to their vasoconstrictor effect.
The variable findings reported in the literature concerning the blood pressure effect of chronic Tx synthetase inhibition in SHR prompted us to explore the role of the elevated renal production of TxA 2 that we have observed in young LH female rats compared with LN controls. 10 This was first investigated in young LH rats by studying the effects of two Tx synthetase inhibitors, Dazmegrel and OKY 046, which are imidazole derivatives of propanoic and propenoic acid, respectively. The extent of Tx synthetase inhibition and its possible consequences on the synthesis of other PGs were assessed by the measurement of the urinary excretion of Txf^, 6-keto-PGF la , and PGE^, which are usually considered a valid index of the renal biosynthesis of TxA 2 , PGI 2 , and PGEz, respectively.
17
. 18 In addition, these urinary measurements track the evolution with age of PG synthesis in the same rats maintained in unstressed physiological conditions. The urinary excretion of TxB 2 and other PGs was determined using a specific method that, because of its chromatographic separation step, allows avoidance of any interference of the 2,3-dinor derivatives of TXB2 and 6-keto-PGF la . Values are mean±SEM. U6K.V, urinary excretion of 6-ketoprostaglandin F la ; UE 2 .V, urinary excretion of prostaglandin E?; UNa.V, urinary excretion of sodium; UK.V, urinary excretion of potassium; LHc, Lyon hypertensive rats given vehicle; LH-Daz, Lyon hypertensive rats given Dazmegrel. Values are mean±SEM. U6K.V, urinary excretion of 6-ketoprostaglandin F ta ; UE2.V, urinary excretion of prostaglandin E^ UNa.V, urinary excretion of sodium; UK.V, urinary excretion of potassium; Creat. Clear., CTeatinine clearance; LHc, Lyon hypertensive rats given vehicle; LH-Daz, Lyon hypertensive rats given Dazmegrel; LH-OKY, Lyon hypertensive rats given OKY 046; LH-AH, Lyon hypertensive rats given AH 23848.
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In these conditions, both Dazmegrel and OKY 046, at the doses used, induced a similar inhibition of renal TxA 2 biosynthesis that was progressive and remained partial, reaching 60% after 6 weeks of treatment. These data are in agreement with those of Grone et al 6 using Dazmegrel (55 mg/kg twice a day) and of Stier and Itzkovitz 21 using OKY 046 (15-20 mg/kg/day) concerning their effects on the renal Tx synthetase. However, the same drugs lowered by 90% the serum TxB 2 concentration. 6 ' 21 This difference may result from a more difficult access of the inhibitors to the glomerular than to the platelet Tx synthetase. 6 ' 22 Such a difficult access could also account for the slow onset of the decrease in the urinary TxB? excretion that we have reported here. The two inhibitors used were specific for the Tx synthetase, as they did not alter the urinary excretion of 6-keto-PGF la and PGE2. In addition, we did not observe any increase in the production of 6-keto-PGF la or PGE2 because of the reuse of accumulating endoperoxides as it was reported in serum or in plasma with 4'-(imidazol-l-yl) acetophenone, 8 Dazoxiben, 2223 and CGS 13080. 23 Our results are in agreement with those of Patrignani et al, 22 Zipser, 24 and Kudo et al, 25 who also studied the renal synthesis of PGs. The results may be explained by the fact that the rate of synthesis of TxA 2 is lower in the kidneys than in the platelets, which makes fewer endoperoxides available for PGI 2 or PGE2 synthesis in that organ.
When considering the antihypertensive effects, the use of female LH rats, which exhibit an SBP level 20 mm Hg below that of age-matched males, 9 did not facilitate our observations. The first attempt in which Dazmegrel treatment was started in 5-week-old LH rats was a failure, which can be explained by the time needed to reduce the activity of the renal Tx synthetase. Therefore, in a second experiment the treatment was started as early as possible (i.e., just after weaning), and we compared the effects of Dazmegrel with those of OKY 046. In these conditions, Dazmegrel transiently reduced the SBP elevation, and OKY 046 normalized it in 6-, 7-, and 8-week-old rats. The more pronounced and longer-lasting antihypertensive effects of OKY 046 compared with Dazmegrel cannot be accounted for by a difference in the Tx synthetase inhibition, as both drugs induced similar decreases in urinary TXB2. This finding raises the possibility of additional pharmacological properties of OKY 046. It is noteworthy that the SBP began to rise 1 week before the end of the treatment with OKY 046. Such an escape, also reported by Shibouta et al 14 27 and to be also devoid of platelet-stabilizing effects unrelated to the TxA 2 receptor blockade. 28 Twelve hours after the end of the long-term treatment (2 mg/kg b.i.d.), AH 23848 inhibited the platelet aggregation by 65%. It did not alter the renal biosynthesis of TxA 2 , PGI 2 , or PGE2, a finding that confirms that this compound does not interfere with cyclooxygenase, PGI 2 synthetase, or isomerase. 1 In our conditions, AH 23848 induced a stable normalization of SBP that, by contrast with OKY 046, persisted 1 week after the end of the treatment.
As a rule, the antihypertensive effect of Tx synthetase inhibitors or of the TxA 2 /PGH 2 receptor blocker appeared after 3 weeks of treatment. Such a delay, which was also reported in SHR, 78 could not be explained by the nature of the drugs used or by an accumulation of endoperoxides with TxA 2 -like actions, as the effects of these latter were also blocked by AH 23848. Therefore, one has to consider that TxA 2 may also act on SBP regulation by mechanisms differing from its direct and immediate vasoconstrictor effect. This could explain the time-dissociated evolution between the inhibition of Tx synthetase and the SBP decrease. Such an hypothesis is supported by our observation that an acute administration of AH 23848 did not reduce the SBP levels and that its inhibitory effects on the pressor action of a TxA 2 /PGH 2 agonist was much shorter lasting than that on platelet aggregation. It is also strengthened by the lack of antihypertensive action reported after acute administration of Tx synthetase inhibitors in SHR 68 - 15 as well as in patients with essential hypertension. 25 These indirect mechanisms could involve an inhibition of the TxA 2 stimulatory effect on norepinephrine release 29 - 30 or on the proliferation of vascular smooth muscle cells. 31 In conclusion, Tx synthetase inhibitors and more markedly TxA2/PGH 2 receptor blockers are efficient antihypertensive drugs in genetically hypertensive rats of the Lyon strain when they are given immediately after weaning. The SBP effects of TxA 2 receptor blocker were found to be more potent and longer lasting than those of Tx synthetase inhibitors. With both classes of compounds, a 3-week delay was required before the decrease in SBP occurred, a finding that points out that the control of blood pressure by TxA 2 may rely largely on indirect mechanisms. Finally, the present work demonstrates that TxA 2 is involved in the long-term blood pressure regulation of LH rats. Despite the absence of treated normotensive controls, it suggests that the increased renal and presumably extrarenal production of TxA 2 observed in young LH rats may be of importance in the pathogenesis of their hypertension.
